home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

17.20 +1.42 (+9.00%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

November 28, 2023

From Novocure

Via Business Wire

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

November 21, 2023

From Novocure

Via Business Wire

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

November 10, 2023

From Novocure

Via Business Wire

Is Novocure Stock a Buy? ↗

November 03, 2023

The stock isn't far from its 52-week low.

Via The Motley Fool

Why Novocure Stock Fell 24.4% This Week ↗

August 31, 2023

Novocure announced a disappointing outcome from a phase 3 clinical trial for a key cancer treatment.

Via The Motley Fool

What 11 Analyst Ratings Have To Say About NovoCure ↗

August 29, 2023

Via Benzinga

Why Novocure Stock Was Sick Today ↗

October 26, 2023

Investors weren't particularly pleased with the company's third-quarter performance.

Via The Motley Fool

NovoCure (NVCR) Q3 2023 Earnings Call Transcript ↗

October 26, 2023

NVCR earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Novocure Reports Third Quarter 2023 Financial Results

October 26, 2023

From Novocure

Via Business Wire

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

October 15, 2023

From Novocure

Via Business Wire

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

October 12, 2023

From Novocure

Via Business Wire

NovoCure Limited (NASDAQ:NVCR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing ↗

October 10, 2023

San Diego, CA -- (SBWIRE) -- 10/10/2023 -- An investigation was announced for investors in shares of NovoCure Limited (NASDAQ:NVCR) concerning potential breaches of fiduciary duties by certain...

Via SBWire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 05, 2023

Via Benzinga

Novocure to Report Third Quarter 2023 Financial Results

October 02, 2023

From Novocure

Via Business Wire

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

September 29, 2023

From Novocure

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

September 29, 2023

Friday's session saw 112 companies set new 52-week lows.

Via Benzinga

3 Things About NovoCure That Smart Investors Know ↗

September 19, 2023

Its cancer-treating device is struggling to find its market.

Via The Motley Fool

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

September 08, 2023

From Novocure

Via Business Wire

3 Healthcare Stocks to Sell in September Before They Crash & Burn ↗

September 06, 2023

The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.

Via InvestorPlace

Down 31% in 1 Day, What's Next for NovoCure Stock? ↗

September 04, 2023

It's entering a risky period, but it could persevere.

Via The Motley Fool

Is NovoCure's Stock Headed for a Free Fall? ↗

August 31, 2023

It can be hard to find a reason to remain bullish on NovoCure.

Via The Motley Fool

Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

August 29, 2023

From Novocure

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

August 29, 2023

On Tuesday, 99 stocks hit new 52-week lows.

Via Benzinga

What's Going On With NovoCure Stock Today? ↗

August 29, 2023

NovoCure Limited (NASDAQ: NVCR) shares are trading higher Tuesday. The stock appears to be recovering from a loss of over 30% on Monday. What To Know:

Via Benzinga

PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday ↗

August 29, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Dow Gains Over 100 Points; Hawaiian Electric Shares Surge ↗

August 28, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Monday. The Dow traded up 0.42% to 34,490.80 while the NASDAQ rose 0.62% to 13,674.49. The S&P 500,...

Via Benzinga

Topics Stocks

Why Is Novocure (NVCR) Stock Down 30% Today? ↗

August 28, 2023

Following Novocure’s disappointing late-stage clinical trial for its cancer-treating platform, NVCR stock stumbled on relevancy concerns.

Via InvestorPlace

Why Is Cancer Focused-Novocure's Stock Plunging Today? ↗

August 28, 2023

Novocure Ltd (NASDAQ: NVCR) shares are falling after the company's phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients...

Via Benzinga

Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 28, 2023

Gainers Mobile Infrastructure Corporation (NASDAQ: BEEP) shares jumped 98.7% to $12.02.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 28, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com